Cofactor Genomics Status
The company raised venture funding from Lagomaj Capital on an undisclosed date.
Developer of a biotechnology platform intended for RNA sequencing and expression analysis. The company's platform examines nearly 600 RNA biomarkers known to be associated with response to targeted therapeutics, enabling biotech companies to commercialize a suite of clinical diagnostic assays targeting oncologic, immunologic, and neurodegenerative diseases
Year Founded
2008
Employees
15
RevenueFY 2014
$4 M
General Information
-
Website
-
Business Status
Generating Revenue
-
Ownership Status
Privately Held (backing)
-
Financing Status
Venture Capital-Backed
Cofactor Genomics News and Updates
Synechococcus nitrogen gene loss in iron-limited ocean regions ...
Nature.com | October 2, 2023
Origin of breath isoprene in humans is revealed via multi-omic ...
Nature.com | September 30, 2023
The oxidoreductase activity of Rnf balances redox cofactors during ...
Nature.com | September 30, 2023
Transcriptome-wide marker gene expression analysis of stress ...
Nature.com | September 27, 2023
Cultivation and genomic characterization of novel and ubiquitous ...
Nature.com | September 25, 2023
Why Pharma Should Pay Attention to – and Be Part of – Rapid ...
FiercePharma | September 24, 2023
Cofactor Genomics's Verticals
Cofactor Genomics Primary Industry Sector / Group / Code
Cofactor Genomics's Trends
Cofactor Genomics Metrics
Growth Rate
SimilarWeb Unique Visitors
Majestic Referring Domains
Twitter Followers
Headquarters
-
HQ Address Line 1300 Brannan Street
-
HQ Address Line 2Suite 410
-
HQ CitySan Francisco
-
HQ State/ProvinceCalifornia
-
HQ Post Code94107
-
HQ CountryUnited States
Cofactor Genomics's Keywords
mood_badFeed is empty.
Add a review